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Abstract Purpose: Suppression of the invasive phenotype
is essential in developing new therapeutic tools to treat
advanced prostate cancer (PC) indicating that androgen-
independent prostate cancer (AI-PC) is characterized by
increased metastatic potential. In the present study, we
have investigated the effect of the nonhypercalcemic
vitamin D analogue BXL-628 on proliferation and
invasive properties of the human PC cell line DU145. In
particular, the effect of the analogue was tested follow-
ing stimulation with a potent growth factor, keratino-
cyte growth factor (KGF), which stimulates both
proliferation and invasion of these cells. We have also
evaluated the effect of the analogue on KGF stimulation
of PI3K/AKT signaling pathway. Methods: Cell prolif-
eration was determined by cell counting. Invasion
through Matrigel was evaluated using Boyden cham-
bers. PI3K activity was measured by immunokinase
assay and AKT phosphorylation was evaluated by
western blot analysis. Keratinocyte growth factor
receptor (KGFR) autotransphosphorylation was evalu-
ated by western blot after immunoprecipitation of the
receptor. Results: BXL-628 is able to inhibit both pro-
liferation and invasion of DU145 cells in basal condi-
tions and in response to KGF. Following stimulation
with KGF, the inhibition is due to suppression of
KGFR autotransphosphorylation and downstream
PI3K/AKT activation, both achieved following a brief
(5 min) incubation with the analogue. This effect on
KGFR autophosphorylation was still present when cells
were treated with the a-amanitin, an inhibitor of RNA
transcription, indicating a rapid, nongenomic effect.
Conclusions: Our results demonstrate that the vitamin D
analogue BXL-628 is able to suppress KGF-induced
proliferation and invasion of AI-PC cells in vitro,
prospecting a possible use of the drug, which is currently
in phase II clinical studies for benign prostatic hyper-
plasia, in the treatment of advanced prostate cancer.
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Phosphatidylinositol 3 kinase Æ VDR: Vitamin D
receptor
Introduction
Prostate Cancer (PC) is one of the most common cancer
and the second leading cause of death in American men
(Gronberg 2003). In the advanced stages of the disease
androgen ablation therapy represents a valuable tool for
the treatment of these patients. However, in almost all
patients androgen-independent (AI) clones of tumor
cells develop after a year of treatment and at this stage
no other efficacious therapies are available. The mech-
anisms responsible for transition to androgen indepen-
dence are still unclear (So et al. 2005), however, a
striking characteristics of androgen-independent pros-
tate cancer (AI-PC) is related to its higher invasive po-
tential compared to androgen-dependent stages (Chung
et al. 2005). In vitro studies using available androgen-
sensitive human PC cell line and androgen-insensitive
human PC cell line indicate that, at least in part, higher
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invasiveness of AI-PC may be due to loss of regulation
of genes involved in invasion (Baldi et al. 2003). Bone
metastases have been reported to occur in 85–100% of
patients with advanced PC. Thus, novel therapies to
increase the chance and the quality of life in patients
with advanced PC should aim at inhibition, besides
proliferation, also the invasive ability of the tumors.
Based on their anti-proliferative, pro-apoptotic and
pro-differentiative properties, vitamin D analogues have
been extensively studied as possible treatments for can-
cer (Nagpal et al. 2005).
Several studies have focused on the role of calcitriol
and its receptor, the vitamin D receptor (VDR), in PC
(Peehl and Feldman 2004) and clinical trials have shown
the capacity of calcitriol to inhibit prostate specific
antigen (PSA) increase in PC patients (Trump et al.
2004). Polymorphisms in the VDR gene have been
implicated as risk factors for PC development and pro-
gression (Habuchi et al. 2000) and the growth inhibitory
effects of calcitriol and its analogues have been well
characterized in PC cells (Nagpal et al. 2005). However,
much less is known about the effect of these compounds
on the invasive ability of PC cells, although calcitriol has
been shown to reduce invasion in PC cells (Sung and
Feldman 2000; Schwartz et al. 1997).
A major problem with the clinical use of calcitriol
is its hypercalcemia-inducing capacity, prompting the
search for less hypercalcemic analogues. The less
hypercalcemic Vitamin D analogue BXL-353 shows a
strong antiproliferative activity in PC cell lines and
benign stromal cell in vitro, being effective at very low
concentrations (Crescioli et al. 2000, 2002). This
compound inhibits in vitro growth of both benign
prostate hyperplasia (BPH) and PC cells by disrupting
KGF-induced growth, decreasing bcl-2 over-expression
and inducing apoptosis (Crescioli et al. 2002, 2003).
Strikingly, the effect of the compound on KGF-in-
duced growth is mediated by inhibition of KGF-in-
duced KGF receptor autotransphosphorylation
following a brief (5 min) treatment (Crescioli et al.
2002), indicating the involvement of a rapid, nonge-
nomic mechanism of the vitamin D analogue on
growth inhibition in PC.
In the present study, we have investigated the effect
of a recently developed vitamin D analogue, BXL-628,
on KGF-induced invasion and proliferation of the
androgen-independent PC cell line DU145. Previous
data from our laboratory demonstrated the capacity of
this analogue to decrease prostate cell proliferation
both in vitro, using primary cultures of human BPH
cells and in vivo, showing inhibition of prostate growth
in intact and castrated, testosterone-replaced, rats
(Crescioli et al. 2004). Based on these data, BXL-628 is
currently being tested in phase II trials for the treat-
ment of benign prostate hyperplasia. Results in the
present study examine the effects of BXL-628 on KGF-
induced autotransphosphorylation of its receptor, and
downstream activation of the PI3K/AKT pathway, in
AI-PC cells.
Materials and methods
Materials
Analogue 1-a-fluoro-25-hydroxy-16,23E-diene-26,27-
bishomo-20-epi-cholecalciferol (BXL-628) was provided
by BioXell (Milan, Italy). Anti-KGFR polyclonal
antibody was purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Antiphosphotyrosine
PY20 antibody and [c-32P]ATP were obtained from
ICN (Costa Mesa, CA, USA). Keratinocyte growth
factor (KGF) was obtained from Prepro Tech EC
(London, England). LY294002 was from Calbiochem
(California, USA). Phosphoinositides were from AV-
ANTI POLAR-Lipids, Inc. (Alabaster, AL, USA).
Protein A and Protein G-Sepharose were obtained
from Amersham Pharmacia Biotech Italia (Cologno
Monzese, Italy). Matrigel was from Becton Dickinson
(Franklin Lakes, NJ, USA). Protein measurement
Coomassie kit was purchased from Bio-Rad Labora-
tories, Inc. (Hercules, CA, USA). Annexin-V-Fluos
staining kit was obtained from Roche Molecular Bio-
chemicals (Milan, Italy). DMEM, antibiotics, and
other not specified reagents were purchased from
SIGMA Chemical Co. (St. Louis, MO, USA).
Cell culture
Androgen independent human cell lines, DU145 and
PC3, were obtained from American Tissue Culture
Collection (Bethesda, Maryland, USA) and maintained,
respectively, in DMEM and HAM-F12 Coon supple-
mented with 10% FBS, penicillin (100 UI/ml), strepto-
mycin (10 mg/ml), and glutamine (2 mM).
Cell proliferation assay
All proliferation tests were performed after 24 h of cell
starvation in phenol red- and serum-free medium con-
taining 0.1% BSA. After starvation, cells were incubated
in the same medium as before, with or without specific
stimuli. Thereafter, cells were trypsinized, and each
experimental point was derived from counting in the
hemocytometer and then averaging at least six different
fields for each well as previously reported (Crescioli et al.
2003). Experiments were performed seeding 4·104 cells
onto 12-well plates in growth medium and incubated for
48 h with (1) increasing concentrations of BXL-628
(1·1012, 1·1011, 1·1010, 1·109, 1·108 M) with or
without fixed concentration of KGF (10 ng/ml) or fixed
concentration of bFGF (10 ng/ml); (2) fixed concentra-
tion of LY 294002 (10 nM) with or without KGF
(10 ng/ml). In the same experiment each experimental
point was repeated in triplicate and experiments were
performed at least three times. Cell growth results are
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expressed as the percentage of growth compared with
their relative controls.
Invasion assay
Invasion assays were performed as described previously
(Bonaccorsi et al. 2000, 2004a, b) according to Albini
et al. (1987) using the Boyden chambers equipped with
8 lm porosity polyvinylpyrrolidone-free polycarbonate
filters (VWR International, Milan, Italy). A thin layer of
Matrigel solution (50 lg/ml) was overlaid on the upper
surface of the filter and allowed to gel by incubating the
filters at 37C for 30 min. Cell ability to invade the
substrate was assessed by using some different stimuli:
KGF (10 ng/ml), in presence or in absence of the
inhibitor, BXL-628 (1·108 M). These molecules were
added to the bottom well of the Boyden chambers. Cells
(9.5·104) were then added to the top of the chambers
and incubated for 24 h at 37C. Migrated cells were
quantitated by counting cells with a Zeiss microscope
(Oberkochen, Germany) equipped with brightfield
optics (40· magnification). Results are expressed as the
percentage of number of migrated cells per high-power
field with respect to control.
Immunoprecipitation and Western blot analysis
Protein extraction and immunoprecipitation were per-
formed as previously described (Bonaccorsi et al. 1997).
Briefly, cells were scraped in PBS supplemented with
1 mM Na3VO4, centrifuged and resuspended in lysis
buffer [20 mM Tris, pH 7.4, 150 mM NaCl, 0.25% NP-
40, 1 mM Na3VO4, 1 mM phenylmethyl-sulfonyl fluo-
ride (PMSF)]. After protein measurement (Coomassie
kit), aliquots of cell lysates containing equal amount of
proteins (500 lg) were incubated for 1 h with 30 ll of
Protein A (or Protein G)-Sepharose for preclearing.
Precleared lysates were then incubated for 1 h using 5 lg
of specific anti-KGFR antibodies on ice followed by
overnight incubation at 4C with 30 ll of Protein A (or
Protein G)-Sepharose. The immunobeads were washed
three times in lysis buffer and then resuspended in 10 ll
of 2· Laemmli’s reducing sample buffer (62.5 mM Tris
pH 6.8, 10% glycerol, 2% SDS, 2.5% pyronin, and
200 mM dithiothreitol), boiled at 95C for 5 min and
loaded onto 8% polyacrylamide–bisacrylamide gels.
After SDS-PAGE, proteins were transferred to nitro-
cellulose membrane (Sigma Co., St. Louis, MO, USA)
and incubated with the specific primary antibodies for
2 h in 1% BM blocking (Roche, Milan, Italy) in TTBS
solution (Tris-buffered saline containing 0.1% Tween
20, pH 7.4), washed and incubated with peroxidase-
conjugated relative secondary antibodies (1:4,000) for
2 h. After washing, the blots were incubated with en-
hanced chemiluminescence (BM, Roche, Milan, Italy)
detection reagent and exposed to film. After the first
blotting, nitrocellulose membranes were stripped at
50C for 30 min in stripping buffer (100 mM 2b-mer-
captoethanol, 2% sodium dodecyl sulphate, 62.5 mM
Tris–HCl pH 6.7) and re-probed with specific primary
antibodies to detect different proteins.
Annexin-V binding assay
Annexin-V binding assay was used to detect transloca-
tion of membrane phosphatidylserine (PS) from the inner
to the outer side of the plasma membrane, since the
exposure of PS is considered an early sign of apoptosis
(Kagan et al. 2000). The assay was performed by using
the ‘‘Annexin-V-Fluos staining Kit’’ (Roche). Before
treatment, cells (1·106) were kept in serum-free medium
for at least 24 h, then cells were incubated for 8 h in the
presence or absence of BXL-628 (1·108 M), then cells
(1·106) were washed, tripsinized, centrifuged. After two
washes in PBS, cells were resuspended in 100 ll of
incubation buffer (supplied by manufacturer), 2 ll of
Annexin-V-Fluos labeling reagent (Ann-V-F, Annexin-V
conjugated to fluorescein, supplied at the 200· concen-
tration by Roche), and 2 ll of propidium iodide solution
(PI, 30 lg/ml in PBS) were added. After incubation
(15 min in the dark at room temperature) samples were
analyzed by flow cytometry. For each experimental set,
two cell suspensions were prepared for instrumental
setting and data analysis: (1) by omitting both Ann-V-F
and PI staining (nonspecific fluorescence sample), and (2)
by omitting only the PI staining (sample for compensa-
tion, see below). Ann-V-F green fluorescence and PI red
fluorescence were revealed by using FL-1 and FL-2
detectors, respectively. Fluorescence compensation was
set by acquiring sperm labeled with only Ann-V-F. For
each sample 10,000 events were recorded at a flow rate of
200/300 cells/s. Debris was gated out by establishing a
region around the population of interest, in the Forward
Scatter/Side Scatter (FSC/SSC) dot plot. Quadrant set-
ting was established in the FL-1/FL-2 dot plot corre-
sponding to the autofluorescence sample by including
more than 99% of total events in the lower left quadrant.
PI3K assay
PI3K activity was evaluated in vitro assay as previously
described (Luconi et al. 2004). Briefly, cells were stimu-
lated with KGF (5 min) in the presence or absence of
BXL-628, scraped in PBS supplemented with 1 mM
Na3VO4, centrifuged and extracted with lysis buffer
(20 mM Tris, pH 7.4, 137 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, 1% NP-40, 1 mM Na3VO4, 1 mM
PMSF). After measurement of proteins, the aliquots of
cell extracts containing equivalent amount of proteins
(500 lg) were incubated for 1 h with 50 ll of Protein G-
Sepharose for preclearing. Precleared lysates were then
incubated with an antiphosphotyrosine PY20 antibody
overnight at 4C with 50 ll of Protein G-Sepharose as
described above. The Sepharose beads were washed two
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times with lysis buffer and twice with a 10 mM Tris–HCl
(pH 7.4) containing 0.1 mM EGTA and 5 mM LiCl.
After removal from the last wash, the beads were sus-
pended in kinase buffer (10 mM Tris–HCl, 150 mM
NaCl, 5 mM EDTA) containing 20 lg of L-a-phospha-
tidylinositol, 25 mM MgCl2, and 10 lCi of [c-
32P]ATP,
and incubated for 20 min at room temperature. The
reaction was stopped by the addition of 60 ll of HCl
6 M and 160 ll of a mixture of chloroform and meth-
anol (1:1). Lipids were then resolved by thin layer
chromatography plates, TLC silica gel 60 (Merck
Laborchimica, Florence, Italy), in chloroform, metha-
nol, water, and ammonium hydroxide (60:47:11.3:2).
Dried TLC sheets were developed by autoradiography.
Quantifications of the bands were performed using a
Kodak image analysis system.
Statistical analysis
All the data are shown as mean ± SEM of the indicated
number of experiments. Statistical analysis was per-
formed with ANOVA and Student’s t test for unpaired
and, when applicable, for paired data. IC50 for dose–
response curves was calculated using the program
ALLFIT.
Results
Inhibitory effects of BXL-628 on basal
and KGF-mediated proliferation of DU145 cells
As shown in the inset of Fig. 1, treatment with the vita-
min D analogue BXL-628 inhibits dose dependently
DU145 cell proliferation with an IC50 of 22.1±19.1 pM.
Similar results are obtained when cell proliferation was
assessed using the MTT assay (results not shown). As
shown in Fig. 1, KGF stimulates DU145 cell prolifera-
tion at the concentration of 10 ng/ml. Treatment with
BXL-628 completely and dose dependently inhibits
proliferation stimulated by the growth factor (Fig. 1).
Similar effects were also observed in the AI cell line PC3
[percentage number of cells: 100±17 control, 121.3±13
KGF (10 ng/ml), 69.9±9.9 KGF + BXL-628
(1·108 M)], although, in line with previous work by our
group (Crescioli et al. 2002), responsiveness of PC3 cells
to KGF was lower with respect to DU145. To evaluate
whether the inhibitory effects of BXL-628 were specific
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Fig. 1 Effect of BXL-628 on basal (inset) and KGF-stimulated
proliferation of DU145 cells, determined by cell counting. Cells
were treated for 48 h with increased concentrations of the
analogue with or without fixed concentrations of KGF (10 ng/
ml). Each experimental point was determined in triplicate and
experiments were performed at least three times. Results are
expressed as the percentage of growth compared with their
relative controls
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for KGF, we tested its effect on bFGF-stimulated pro-
liferation of DU145 cells. Our results demonstrated an
inhibitory effect of BXL-628 also on bFGF-mediated
proliferation [percentage number of cells: 100±8.6
control, 138±19.5 bFGF (10 ng/ml), 74.1±9.2
bFGF + BXL-628 (1·108 M)].
Previous studies from our group (Crescioli et al. 2000,
2002) indicate that vitamin D analogues exert in part
their antiproliferative effects by inducing cell apoptosis.
To evaluate whether the inhibitory effect of BXL-628 on
DU145 proliferation was due to induction of apoptosis,
we evaluated phosphatidylserine exposure (an early sign
of cell apoptosis, for review see Kagan et al. 2000) in live
cells by Annexin-V binding after 8-h incubation in the
presence of the analogue (1·108 M). We found that
BXL-628 induces a significant increase of Annexin-V
binding to the cells (percentage Annexin-V positive live
cells: 57±1.7 control, 62±1.2 BXL-628, n=6,
P=0.017).
Effect of BXL-628 on KGF-induced Matrigel invasion
of DU145 cells
Next, we investigated the effect of BXL-628 on KGF-
stimulated Matrigel invasion. Previous studies investi-
gating the effects of vitamin D analogues on cancer cell
invasion and migration utilized long-term treatment
protocols with at least 48 h cell preincubation before
performing the invasion assay (Yudoh et al. 1999; Koli
andKeski-Oja 2000; Schwartz et al. 1997). The inhibitory
effect ofKGF-inducedKGFRautotransphosphorylation
obtained after short-term (5 min) exposure toBXL-353 in
BPH and PC cells (Crescioli et al. 2002) prompted us to
evaluate the effect of BXL-628 on in vitro invasiveness of
DU145 cells avoiding preincubation of the cells with the
analogue, which was added directly to the bottom of
Boyden chambers. As shown in Fig. 2 (panel a), the
stimulatory effect of KGF on DU145 cell invasion is
completely inhibited by the vitamin D analogue at the
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Fig. 2 Effect of BXL-628
(1·108 M) on Matrigel
invasion of DU145 cells (panel
a) and PC3 cells (panel b) in
basal conditions and following
stimulation with KGF (10 ng/
ml). Matrigel invasion was
evaluated by using Boyden
chambers. Number of cells
migrated was evaluated in at
least ten fields for each
experimental point and
averaged. Data are
mean ± SEM of the
percentage of cell migrated with
respect to control of four
different experiments
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concentration of 1·108 M. Similar results were observed
in the PC3 cell line (Fig. 2, panel b).
Effects of BXL-628 on KGF-induced signaling
pathways
Next, we sought to investigate the effects of the com-
pound on KGF-induced signaling in DU145 cells. In
particular, we evaluated the effect of the analogue on
KGFR autotransphosphorylation and on the down-
stream signaling pathway PI3K/AKT. Cells were pre-
treated for a short time (5 min) with BXL-628 before
addition of KGF. For autotransphosphorylation stud-
ies, KGF receptor was immunoprecipitated using spe-
cific antibody. As shown in Fig. 3a, BXL-628 abrogated
KGF-induced autotransphosphorylation of its receptor.
Interestingly, this effect was obtained following a brief
(5 min) preincubation with the analogue, suggesting a
rapid, nongenomic effect. To further investigate this
possibility, we used the RNA transcription inhibitor a-
amanitin. As shown in Fig. 3b, the inhibitory effect of
BXL-628 was still present when the experiment was
conducted following 4-h incubation with 4 lg/ml a-
amanitin, strongly indicating absence of transcriptional
regulation in the inhibitory effect of BXL-628 on KGFR
autophosphorylation.
In view of the key role exerted by the PI3K/AKT
signaling pathway on invasion and migration of PC3
cells (Bonaccorsi et al. 2004a) as well as on KGF-med-
iated proliferation of DU145 cells (Fig. 4) where the
inhibitory effect of the PI3K inhibitor LY294002 on
KGF-induced proliferation of DU145 cells is shown, we
evaluated the effect of BXL-628 on KGF-induced PI3K
activation. As shown in Fig. 5, BXL-628 inhibits the
stimulatory effect of KGF on PI3K activity. Next, we
evaluated the effect of the compound on the main
downstream PI3K effector, the serine/threonine kinase
AKT (Wymann and Pirola 1998). AKT is activated by
serine/threonine phosphorylation following PI3K acti-
vation and this phosphorylation is essential for its
activity. When AKT is activated, it regulates a variety of
cellular functions including cell survival, cell growth, cell
differentiation, cell cycle progression, and cell metabo-
lism (Paez and Sellers 2003). Thus, we evaluated serine
phosphorylation of AKT by Western blot analysis,
employing a specific anti-serine phosphorylated AKT
antibody, following DU145 cell stimulation with KGF
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Fig. 3 Effect of BXL-628 (1·108 M) on KGF (10 ng/ml)-induced
autotransphosphorylation of its receptor. Cells were pre-treated
(panel b) or not (panel a) for 4 h with a-amanitin (4 lg/ml, 4 h).
After stimulations, cell lysates were immunoprecipitated using anti-
KGFR antibody, run onto SDS-PAGE and analyzed first for
expression of phosphorylation using anti-phosphotyrosine (PY20)
antibody (upper blots) and, after stripping and re-probing, for
receptor expression using anti-KGFR and, for the experiment with
a-amanitin, for actin expression. Representative of two similar
experiments
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Fig. 4 Effect of the
phosphatidylinositol-3 kinase
inhibitor, LY294002, on
proliferation of DU145 cells,
determined by cell counting.
Cells were treated for 48 h with
fixed concentration of
LY294002 (10 nM) with or
without KGF (10 ng/ml). Each
experimental point was
determined in triplicate and
experiments were performed at
least three times. Results are
expressed as the percentage of
growth compared with their
relative controls
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in the presence or absence of BXL-628. BXL-628
inhibits KGF-stimulated AKT serine phosphorylation
(Fig. 6) in agreement with the results on receptor auto-
transphosphorylation (Fig. 3) and PI3K activity
(Fig. 5).
Discussion
Prostrate cancer in advanced stages is a fatal disease
because of failure of androgen deprivation therapy and
lack of alternative effective therapy. An ideal therapeutic
agent for AI-PC should target both proliferation as well
as invasive and metastatic properties of the tumor cells,
since once progressed to androgen independence, PC is
characterized also by higher invasive ability (Chung
et al. 2005). The present study demonstrates, for the first
time, that the vitamin D analogue BXL-628 is able to
reduce both proliferation and invasive ability of the AI-
PC cell lines, DU145 and PC3, in basal conditions and in
response to a main growth factor, namely KGF, impli-
cated in proliferation, progression, and invasion of PC
(Russell et al. 1998). At least in part, the antiproliferative
effect of BXL-628 is due to induction of apoptosis, as
demonstrated by increased surface exposure of PS in live
cells after treatment with the analogue. This result is in
line with previous data from our group showing induc-
tion of apoptosis by vitamin D analogues in several cell
types (Crescioli et al. 2000, 2002, 2003, 2004).
Keratinocyte growth factor (KGF) is a physiological
paracrine factor for prostate epithelial cells produced by
stromal cells under the control of androgen (Planz et al.
1999a), but in the case of PC the paracrine loop is mostly
replaced by an autocrine one (Planz et al. 1999b) with
enhanced effectiveness on cell proliferation. Thus, the
growth factor and its receptor represent an important
target for therapeutic strategies in advanced PC. Several
receptor tyrosine kinase (RTK) inhibitors have been
developed in recent years to specifically block RTKs
such as EGFR, VGFR, and FGFR (Noble et al. 2004).
Among these, Gefitinib, an inhibitor of EGFR tyrosine
kinase, has been shown to effectively block, in vitro,
EGFR signaling and EGF-mediated proliferation and
invasion of PC cell lines (Vicentini et al. 2003; Bonac-
corsi et al. 2004b). However, despite clear effectiveness
in other solid tumors (Blay et al. 2005), results of a phase
II clinical trial for PC with this inhibitor were disap-
pointing (Canil et al. 2005). Lack of effectiveness of
Gefitinib has been demonstrated also for renal and
bladder cancers (Drucker et al. 2003; Petrylak et al.
2003) although abnormal EGFR expression/signaling
has been demonstrated in these malignancies, suggesting
tissue selectivity for these agents. It is likely that com-
bination with other therapies is required for the treat-
ment of these malignancies. Here, we show that BXL-
628, consistent with previous results obtained with
vitamin D analogue BXL-353 (Crescioli et al. 2002), is
able to inhibit, as RTK inhibitors, KGFR auto-
transphosphorylation in DU145 cells through a rapid,
likely nongenomic, mechanism of action. Although
further studies are needed to define the molecular
mechanism underlying KGFR tyrosine phosphorylation
inhibition, the demonstration that the downstream
PI3K/AKT pathway is also inhibited, suggests that
BXL-628 is effective in blocking KGF action. As men-
tioned above, BXL-628 is less hypercalcemic compared
to calcitriol and other analogues. In addition, BXL-628
is currently being tested in phase II clinical trials for the
treatment of BPH and preliminary results indicate sig-
nificant reduction of prostate volume compared to pla-
cebo adverse effects (Montorsi F, presentation at the
EUA, Istanbul, March 2005), strongly indicating that
the prostate is a target for this drug.
In conclusion, our results show that the nonhyper-
calcemic vitamin D analogue, BXL-628, is able to block
proliferation and invasion in response to KGF in the AI
cell line DU145. Together with several evidence in the
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SEM quantification (arbitrary units) of the band for the indicated
number of experiments
C    BXL-628  KGF   BXL+KGF
62 kDa
62 kDa AKT
P ser-AKT
Ib:
Fig. 6 Effect of BXL-628 (1·108 M) on KGF (10 ng/ml)-medi-
ated phosphorylation of the PI3K downstream effector AKT. After
stimulation, equal amount of total cell lysates was subjected to
SDS-PAGE, transferred to nitrocellulose membranes, and blotted
with anti-phosphoserine AKT antibodies (upper panels) followed
by stripping and re-probing with anti-AKT antibodies (lower
panels). Representative of two similar experiments
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literature pointing out a differentiating role of calcitriol
and its analogues in carcinoma cells (Stewart and Weigel
2004), our data provide a rationale for the development
of novel analogues to be employed in the treatment of
AI or advanced PC. As previously suggested (Beer et al.
2005) these analogues may be used in combination with
other antineoplastic agents (such as RTK inhibitors) to
induce additive or synergistic effects by simultaneously
targeting multiple components of the same pathway or
several targets at the same time. On the other hand,
targeting multiple signaling pathways appears to be the
most practicable way in approaching prostate cancer
(McCarty 2004).
Acknowledgements This work was supported by AIRC (Milan,
grant to Mario Maggi), Italian Ministry of Education (Progetti Di
Rilevanza Nazionale, PRIN, to Gianni Forti) and BIOXELL
(Milan, Italy).
References
Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA,
Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for
quantitating the invasive potential of tumor cells. Cancer Res
47:3239–3245
Baldi E, Bonaccorsi L, Forti G (2003) Androgen receptor: good
guy or bad guy in prostate cancer invasion? Endocrinology
144:1653–1655
Beer TM, Myrthue A, Eilers KM (2005) Rationale for the devel-
opment and current status of calcitriol in androgen-independent
prostate cancer. World J Urol 23:28–32
Blay JY, Le Cesne A, Alberti L, Ray-Coquart I (2005) Targeted
cancer therapies. Bull Cancer 92:E13–E18
Bonaccorsi L, Luconi M, Maggi M, Muratori M, Forti G, Serio M,
Baldi E (1997) Protein tyrosine kinase, mitogen-activated pro-
tein kinase and protein kinase C are involved in the mitogenic
signaling of platelet-activating factor (PAF) in HEC-1A cells.
Biochim Biophys Acta 1355:155–166
Bonaccorsi L, Carloni V,MuratoriM, Salvadori A,Giannini A,Carini
M, SerioM, Forti G, Baldi E (2000) Androgen receptor expression
in prostate carcinoma cells suppresses alpha6beta4 integrin-medi-
ated invasive phenotype. Endocrinology 141:3172–3182
Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti
G, Baldi E (2004a) EGF receptor (EGFR) signaling promoting
invasion is disrupted in androgen-sensitive prostate cancer cells
by an interaction between EGFR and androgen receptor (AR).
Int J Cancer 112:78–86
Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E (2004b)
Gefitinib (‘IRESSA’, ZD1839) inhibits EGF-induced invasion
in prostate cancer cells by suppressing PI3 K/AKT activation. J
Cancer Res Clin Oncol 130:604–614
Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN,
Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McK-
enna A, Seymour L (2005) Randomized phase II study of two
doses of gefitinib in hormone-refractory prostate cancer: a trial
of the National Cancer Institute of Canada-Clinical Trials
Group. J Clin Oncol 23:455–460
Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular
insights into prostate cancer progression: the missing link of
tumor microenvironment. J Urol 173:10–20
Crescioli C, Maggi M, Vannelli GB, Luconi M, Salerno R, Barni T,
Gulisano M, Forti G, Serio M (2000) Effect of a vitamin D3
analogue on keratinocyte growth factor-induced cell prolifera-
tion in benign prostate hyperplasia. J Clin Endocrinol Metab
85:2576–2583
Crescioli C, Maggi M, Luconi M, Vannelli GB, Salerno R, Sinisi
AA, Bonaccorsi L, Ferruzzi P, Barni T, Forti G, Serio M (2002)
Vitamin D3 analogue inhibits keratinocyte growth factor sig-
naling and induces apoptosis in human prostate cancer cells.
Prostate 50:15–26
Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A,
Muratori M, Scaltriti M, Vannelli GB, Smiroldo S, Mariani R,
Villari D, Bettuzzi S, Serio M, Adorini L, Maggi M (2003)
Inhibition of spontaneous and androgen-induced prostate
growth by a nonhypercalcemic calcitriol analog. Endocrinology
144:3046–3057
Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Man-
cina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E,
Adorini L, Maggi M (2004) Inhibition of prostate cell growth
by BXL-628, a calcitriol analogue selected for a phase II clinical
trial in patients with benign prostate hyperplasia. Eur J Endo-
crinol 150:591–603
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar
M, Motzer R (2003) Phase II trial of ZD1839 (IRESSA) in
patients with advanced renal cell carcinoma. Invest New Drugs
21:341–345
Gronberg H (2003) Prostate cancer epidemiology. Lancet 361:859–
864
Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T,
Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J,
Ogawa O, Kato T (2000) Association of vitamin D receptor
gene polymorphism with prostate cancer and benign prostatic
hyperplasia in a Japanese population. Cancer Res 60:305–308
Kagan VE, Fabisiak JP, Shvedova AA, Tyurina YY, Tyurin VA,
Schor NF, Kawai K (2000) Oxidative signaling pathway for
externalization of plasma membrane phosphatidylserine during
apoptosis. FEBS Lett 477:1–7
Koli K, Keski-Oja J (2000) 1alpha,25-dihydroxyvitamin D3 and its
analogues down-regulate cell invasion-associated proteases in
cultured malignant cells. Cell Growth Differ 11:221–229
Luconi M, Carloni V, Marra F, Ferruzzi P, Forti G, Baldi E (2004)
Increased phosphorylation of AKAP by inhibition of phos-
phatidylinositol 3-kinase enhances human sperm motility
through tail recruitment of protein kinase A. J Cell Sci
117:1235–1246
McCarty MF (2004) Targeting multiple signaling pathways as a
strategy for managing prostate cancer: multifocal signal mod-
ulation therapy. Integr Cancer Ther 3:349–380
Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of
vitamin D receptor ligands. Endocr Rev 26(5):662–687
Noble ME, Endicott JA, Johnson LN (2004) Protein kinase
inhibitors: insights into drug design from structure. Science
303:1800–1805
Paez J, Sellers WR (2003) PI3K/PTEN/AKT pathway. A critical
mediator of oncogenic signaling. Cancer Treat Res 115:145–167
Peehl DM, Feldman D (2004) Interaction of nuclear receptor li-
gands with the Vitamin D signaling pathway in prostate cancer.
J Steroid Biochem Mol Biol 92:307–315
Petrylak D, Faulkner JR, Van Veldhuizen PJ et al (2003) Evalua-
tion of ZD1839 for advanced transitional cell carcinoma (TCC)
of the urothelium: a Southwest Oncology Group Trial (abstract
1619). Proc Am Soc Clin Oncol 22:403
Planz B, Aretz HT, Wang Q, Tabatabaei S, Kirley SD, Lin CW,
McDougal WS (1999a) Immunolocalization of the keratinocyte
growth factor in benign and neoplastic human prostate and its
relation to androgen receptor. Prostate 41:233–242
Planz B, Kirley SD, Wang Q, Tabatabaei S, Aretz HT, McDougal
WS (1999b) Characterization of a stromal cell model of the
human benign and malignant prostate from explant culture. J
Urol 161:1329–1336
Russell PJ, Bennett S, Stricker P (1998) Growth factor involvement
in progression of prostate cancer. Clin Chem 44:705–723
Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1
alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasive-
ness of human prostate cancer cells. Cancer Epidemiol Bio-
markers Prev 6:727–732
415
So A, Gleave M, Hurtado-Col A, Nelson C (2005) Mechanisms of
the development of androgen independence in prostate cancer.
World J Urol 23:1–9
Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp
Biol Med (Maywood) 229:277–284
Sung V, Feldman D (2000) 1,25-Dihydroxyvitamin D3 decreases
human prostate cancer cell adhesion and migration. Mol Cell
Endocrinol 164:133–143
Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J,
Fakih M, Yu WD, Johnson CS (2004) Anti-tumor activity of
calcitriol: pre-clinical and clinical studies. J Steroid Biochem
Mol Biol 89–90:519–526
Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A,
Bologna M (2003) Prostate cancer cell proliferation is strongly
reduced by the epidermal growth factor receptor tyrosine kinase
inhibitor ZD1839 in vitro on human cell lines and primary
cultures. J Cancer Res Clin Oncol 129:165–174
Wymann MP, Pirola L (1998) Structure and function of
phosphoinositide 3-kinases. Biochim Biophys Acta
1436:127–150
Yudoh K, Matsuno H, Kimura T (1999) 1alpha,25-dihydroxyvi-
tamin D3 inhibits in vitro invasiveness through the extracellular
matrix and in vivo pulmonary metastasis of B16 mouse mela-
noma. J Lab Clin Med 133:120–128
416
